241 related articles for article (PubMed ID: 33479765)
1. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(4):604-611. PubMed ID: 33479765
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
4. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Takahashi S; Sueda T
Cancer Chemother Pharmacol; 2017 Jan; 79(1):37-47. PubMed ID: 27878355
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
8. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial.
Uemura K; Kondo N; Sudo T; Sumiyoshi T; Shintakuya R; Okada K; Baba K; Harada T; Murakami Y; Takahashi S
J Hepatobiliary Pancreat Sci; 2024 May; 31(5):351-362. PubMed ID: 38156372
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Motoi F; Kosuge T; Ueno H; Yamaue H; Satoi S; Sho M; Honda G; Matsumoto I; Wada K; Furuse J; Matsuyama Y; Unno M;
Jpn J Clin Oncol; 2019 Feb; 49(2):190-194. PubMed ID: 30608598
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer.
Saito K; Isayama H; Sakamoto Y; Nakai Y; Ishigaki K; Tanaka M; Watadani T; Arita J; Takahara N; Mizuno S; Kogure H; Ijichi H; Tateishi K; Tada M; Hasegawa K; Fukayama M; Kokudo N; Koike K
Med Oncol; 2018 May; 35(7):100. PubMed ID: 29846849
[TBL] [Abstract][Full Text] [Related]
12. [Tolerability and Outcome of Neoadjuvant GS Therapy for Resectable Pancreatic Cancer].
Yamashita M; Shimizu J; Sato Y; Noma T; Hagihara K; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Akagi K; Iwasawa S; Tomita N
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1411-1413. PubMed ID: 38303291
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Xu Y; Guo X; Fan Y; Wang D; Wu W; Wu L; Liu T; Xu B; Feng Y; Wang Y; Lou W; Zhou Y
Jpn J Clin Oncol; 2018 Jun; 48(6):535-541. PubMed ID: 29718363
[TBL] [Abstract][Full Text] [Related]
14. A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma.
Eguchi H; Takeda Y; Takahashi H; Nakahira S; Kashiwazaki M; Shimizu J; Sakai D; Isohashi F; Nagano H; Mori M; Doki Y
Ann Surg Oncol; 2019 Dec; 26(13):4498-4505. PubMed ID: 31440928
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Imaoka H; Kou T; Tanaka M; Egawa S; Mizuno N; Hijioka S; Hara K; Yazumi S; Shimizu Y; Yamao K
Eur J Cancer; 2016 Feb; 54():96-103. PubMed ID: 26741729
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
[TBL] [Abstract][Full Text] [Related]
19. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].
Mataki Y; Shinchi H; Maemura K; Kurahara H; Kawasaki Y; Desaki R; Ueno S; Sakoda M; Iino S; Higashi M; Takao S; Natsugoe S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1637-40. PubMed ID: 24393873
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus S-1 for metastatic pancreatic cancer.
Zhu H; Yi C; Zhao Y; Gou H
Medicine (Baltimore); 2018 Oct; 97(41):e12836. PubMed ID: 30313120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
